Brief: Mesoblast Says FDA Schedules Pre-License Inspection Of Remestemcel-L Manufacturing
22/03/2023 01:22
March 21 (Reuters) - Mesoblast Ltd MSB.AX :
* FDA SCHEDULES PRE-LICENSE INSPECTION OF REMESTEMCEL-L
MANUFACTURING
* PDUFA GOAL DATE AUGUST 2, 2023
* BIOLOGICS LICENSE APPLICATION RESUBMISSION FOR PEDIATRIC
ACUTE
GRAFT-VERSUS-HOST DISEASE (SR-AGVHD) CURRENTLY BEING REVIEWED
Source text for Eikon: ID:nGNX4w8Kjw
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M